Table 2 The HR for each individual bone marker and the effect on CVD
From: Bone markers and cardiovascular risk in type 2 diabetes patients
Q1 | Q2 | Q3 | Q4 | Ptrend | Continuous | |
|---|---|---|---|---|---|---|
Osteocalcin | ||||||
(Median, ng/ml) | 14.22 | 19.68 | 25.45 | 34.75 | ||
Events | 33/68 | 41/80 | 29/67 | 31/73 | Per 5 ng/ml | |
Model 1 | Ref | 0.91 (0.58–1.42) | 0.74 (0.44–1.25) | 0.83 (0.51–1.35) | 0.40 | 1.01 (0.98–1.02) |
Model 2 | Ref | 0.90 (0.59–1.47) | 0.94 (0.55–1.60) | 1.10 (0.67–1.81) | 0.64 | 1.01 (0.99–1.02) |
Model 3 | Ref | 0.83 (0.51–1.36) | 0.92 (0.53–1.59) | 1.17 (0.70–1.93) | 0.43 | 1.01 (1.00–1.03) |
Osteopontin | ||||||
(Median, ng/ml) | 8.84 | 11.66 | 13.78 | 18.72 | ||
Events | 23/63 | 31/70 | 36/74 | 44/81 | Per 5 ng/ml | |
Model 1 | Ref | 1.18 (0.70–1.97) | 1.51 (0.89–2.56) | 1.70 (1.03–2.78) | 0.02 | 1.08 (0.97–1.20) |
Model 2 | Ref | 1.34 (0.78–2.33) | 1.79 (1.06–3.02) | 1.76 (1.08–2.88) | 0.02 | 1.08 (0.98–1.20) |
Model 3 | Ref | 1.36 (0.76–2.44) | 1.66 (0.95–2.89) | 2.00 (1.20–3.35) | < 0.01 | 1.11 (1.01–1.21) |
Osteonectin | ||||||
(Median, ng/ml) | 71.78 | 103.40 | 127.9 | 195.6 | ||
Events | 29/70 | 23/65 | 41/75 | 41/78 | Per 10 ng/ml | |
Model 1 | Ref | 0.83 (0.48–1.44) | 1.63 (1.02–2.60) | 1.39 (0.85–2.20) | 0.08 | 1.02 (1.00–1.03) |
Model 2 | Ref | 0.77 (0.44–1.32) | 1.32 (0.82–2.14) | 1.16 (0.72–1.88) | 0.30 | 1.02 (1.00–1.04) |
Model 3 | Ref | 0.74 (0.43–1.27) | 1.25 (0.76–2.05) | 1.16 (0.72–1.88) | 0.30 | 1.02 (1.00–1.04) |
Osteoprotegerin | ||||||
(Median, ng/ml) | 134.4 | 168.3 | 199.0 | 256.6 | ||
Events | 30/69 | 28/69 | 32/73 | 44/77 | Per 10 ng/ml | |
Model 1 | Ref | 0.88 (0.53–1.46) | 0.91 (0.56–1.46) | 1.51 (0.91–2.52) | 0.07 | 1.03 (1.00–1.06) |
Model 2 | Ref | 0.82 (0.50–1.36) | 0.87 (0.53–1.44) | 1.13 (0.65–1.98) | 0.46 | 1.01 (0.98–1.04) |
Model 3 | Ref | 0.88 (0.52–1.47) | 0.84 (0.49–1.45) | 1.23 (0.69–2.19) | 0.35 | 1.01 (0.98–1.05) |
Alkaline phosphatase | ||||||
(Median, ng/ml) | 42.0 | 51.39 | 59.7 | 74.4 | ||
Events | 35/68 | 31/73 | 25/68 | 43/79 | Per 10 ng/ml | |
Model 1 | Ref | 0.79 (0.49–1.29) | 0.67 (0.40–1.14) | 1.13 (0.71–1.79) | 0.52 | 1.07 (0.94–1.21) |
Model 2 | Ref | 0.74 (0.45–1.22) | 0.67 (0.39–1.16) | 1.03 (0.61–1.73) | 0.64 | 1.02 (0.89–1.18) |
Model 3 | Ref | 0.79 (0.47–1.35) | 0.68 (0.39–1.17) | 1.05 (0.60–1.85) | 0.66 | 1.03 (0.89–1.19) |
Sclerostin | ||||||
(Median, ng/ml) | 40.65 | 53.6 | 67.8 | 93.6 | ||
Events | 29/65 | 35/73 | 42/79 | 28/71 | Per 10 ng/ml | |
Model 1 | Ref | 1.07 (0.65–1.78) | 1.18 (0.74–1.89) | 0.83 (0.49–1.40) | 0.42 | 0.99 (0.97–1.02) |
Model 2 | Ref | 1.05 (0.64–1.73) | 1.04 (0.64–1.67) | 0.76 (0.44–1.32) | 0.27 | 0.99 (0.96–1.02) |
Model 3 | Ref | 1.15 (0.68–1.93) | 1.07 (0.65–1.75) | 0.75 (0.41–1.36) | 0.24 | 0.99 (0.96–1.02) |